This brief describes results from an analysis conducted by PATH comparing the current intramuscular version of depot medroxyprogesterone acetate (DMPA) injectable contraceptive compared with a new formulation packaged in the Uniject™ injection system. The analysis focused on waste management implications, identifying key quantitative and qualitative differences between the two products.
Logistics and Waste Management Benefits of depo-subQ in Uniject
686.3 KB PDF
Hard copies are not available.